Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, a midbrain region critical for smooth, coordinated movement. As these cells die, patients experience tremors, rigidity, slowness of movement, and akinesia, alongside non-motor symptoms such as anxiety. Current therapies, including levodopa, manage symptoms but do not halt the underlying neurodegeneration. That therapeutic gap has pushed scientists toward strategies aimed at protecting neurons before they are lost, and increasingly, that search has led to the gut.

Short-chain fatty acids, or SCFAs, are metabolites generated when intestinal microbes ferment dietary fiber. Butyrate is perhaps the most studied of these molecules, known for its anti-inflammatory properties, its role in maintaining the intestinal barrier, and its capacity to act as a histone deacetylase inhibitor, a mechanism that influences gene expression. Because gut microbiota communicate with the central nervous system through the so-called gut-brain axis, researchers have long suspected that SCFAs could influence neurological disease. The new study set out to test that hypothesis directly, asking whether sodium butyrate could deliver measurable benefit in a validated animal model of Parkinsonism.

The research team, led by scientists from Taipei Medical University and collaborators at institutions across Taiwan, induced hemiparkinsonism in rats by injecting 6-hydroxydopamine, or 6-OHDA, unilaterally into the medial forebrain bundle. This neurotoxin selectively destroys dopaminergic neurons on one side of the brain, producing a reliable and widely used model of the disease’s motor pathology. Twenty-four hours after confirming that the lesion had taken hold, the animals were randomized to receive daily oral sodium butyrate for four weeks, while control groups received vehicle treatment.

The behavioral results were striking. Over the course of the intervention, the treated rats showed significant improvements in locomotor activity, akinesia, and gait, measured through open-field testing and gait analysis performed longitudinally at weeks one and four. The animals also exhibited reduced anxiety-like behavior, an important non-motor feature of Parkinson’s disease that often precedes motor decline in patients. Intriguingly, apomorphine-induced rotations, a classic index of dopamine receptor supersensitivity, were not alleviated by the treatment, suggesting that sodium butyrate’s benefits may operate through pathways that partially diverge from dopaminergic receptor dynamics alone.

To connect functional recovery with structural neuroprotection, the researchers turned to immunohistochemical staining for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis and a standard marker for dopaminergic neurons. The staining revealed a significantly higher survival rate of dopaminergic neurons in the sodium butyrate-treated groups compared with controls. In other words, the behavioral improvements were not merely symptomatic compensation; the compound appeared to be genuinely shielding the vulnerable midbrain neurons from the 6-OHDA insult.

While the study did not fully delineate the mechanism of action, the authors point to plausible pathways. As a histone deacetylase inhibitor, butyrate can promote the expression of neurotrophic factors such as brain-derived neurotrophic factor, or BDNF, which supports neuronal survival and plasticity. Its anti-inflammatory effects may also dampen the neuroinflammatory cascade that accompanies dopaminergic degeneration, and its role in reinforcing gut barrier integrity could reduce systemic inflammation that indirectly worsens brain pathology. These mechanisms are not mutually exclusive, and the study’s translational framework is designed to allow future work to disentangle them.

The timing of treatment matters. The team initiated sodium butyrate administration within twenty-four hours of lesion confirmation and maintained it for four weeks, an early and sustained intervention strategy. This design choice mirrors a growing consensus in neurodegeneration research that protective therapies must intervene before substantial neuronal loss has occurred. The authors suggest that their model provides a translational framework for investigating the mechanisms of butyrate therapy in Parkinson’s disease and related neurological disorders, potentially guiding dosing schedules and combination strategies for future preclinical and clinical work.

For patients and clinicians, the appeal of sodium butyrate is obvious. It is an orally available, inexpensive compound with a favorable safety profile, already familiar to the human gut as a product of fiber fermentation. If its neuroprotective effects translate to humans, it could one day serve as an adjunctive therapy alongside existing dopaminergic treatments, addressing not just motor symptoms but the non-motor burden of anxiety and gait dysfunction as well. The researchers emphasize, however, that rat models cannot capture every dimension of human Parkinson’s disease, and clinical trials will be needed to establish efficacy, optimal dosing, and long-term safety in people.

Nevertheless, the study strengthens a rapidly expanding body of evidence linking gut-derived metabolites to brain health. As the gut-brain axis moves from scientific curiosity to therapeutic target, compounds like sodium butyrate represent a concrete example of how microbial chemistry might be harnessed against neurodegeneration. For a disease that has resisted every attempt at disease modification for decades, a four-week oral intervention that preserves dopaminergic neurons and restores movement in rats is a result worth watching closely.

Subject of Research: Therapeutic effects of oral sodium butyrate on dopaminergic neurodegeneration in a rat model of Parkinson's disease

Article Title: Oral sodium butyrate alleviates motor deficits and dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson’s disease rat model

Article References: Oral sodium butyrate alleviates motor deficits and dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson’s disease rat model. (n.d.). https://doi.org/10.1186/s12868-026-01046-x

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01046-x

Keywords: sodium butyrate, Parkinson's disease, gut-brain axis, short-chain fatty acids, 6-hydroxydopamine, dopaminergic neurons, neuroprotection, rat model, motor deficits, substantia nigra, microbiota, neurodegeneration